Exelixis Inc. announced the successful results for Cabozantinib in combination with immunotherapies in patients with advanced colorectal cancer.
PromoCell GmbH to lead research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4020
Published Date: May 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing prevalence of colorectal cancer and rising cancer awareness are some of the major factors anticipated to drive the growth of the leucovorin calcium market.
The market is anticipated to attain a CAGR of 16% over the forecast period, i.e., 2023 â€“ 2035.
The High cost of cancer treatment is estimated to hamper the market growth.
The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The major players in the market are Abbott Laboratories, Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by end-user, route of administration, and by region.
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.